<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Corines MJ</submitter><funding>National Institutes of Health National Cancer Institute</funding><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><pagination>111986</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11892329</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>184</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>We explored the use of MRI T2-weighted imaging (T2WI) radiomics to help distinguish acellular mucin from cellular mucin (residual tumor) to inform patient management.&lt;h4>Methods&lt;/h4>This retrospective, multi-institutional study included consecutive patients with rectal adenocarcinoma containing mucin on restaging MRI from March 2012-January 2020. Radiologists segmented 3-mm-thick T2WI. Data were split into training (n = 122), validation (n = 40), and test (n = 42) sets. Sensitivity, specificity, PPV, NPV, and AUC of the developed radiomic models were investigated on the test set. Histopathology was the reference standard. Two radiologists independently reviewed 42 patients using a unique five-point Likert scale for the probability of cellular mucin. DeLong-Delong or McNe</pubmed_abstract><journal>European journal of radiology</journal><pubmed_title>Can MRI radiomics distinguish residual adenocarcinoma from acellular mucin in treated rectal cancer?</pubmed_title><pmcid>PMC11892329</pmcid><funding_grant_id>P30 CA008748</funding_grant_id><pubmed_authors>Lee S</pubmed_authors><pubmed_authors>Sheedy SP</pubmed_authors><pubmed_authors>Schwartz LH</pubmed_authors><pubmed_authors>Zhao B</pubmed_authors><pubmed_authors>Ibrahim A</pubmed_authors><pubmed_authors>Ernst R</pubmed_authors><pubmed_authors>Gollub MJ</pubmed_authors><pubmed_authors>Korngold E</pubmed_authors><pubmed_authors>Miranda J</pubmed_authors><pubmed_authors>Zheng J</pubmed_authors><pubmed_authors>Horvat N</pubmed_authors><pubmed_authors>Nougaret S</pubmed_authors><pubmed_authors>Moreno CC</pubmed_authors><pubmed_authors>Fox M</pubmed_authors><pubmed_authors>Nahas SC</pubmed_authors><pubmed_authors>Baheti A</pubmed_authors><pubmed_authors>Corines MJ</pubmed_authors><pubmed_authors>Gangai N</pubmed_authors><pubmed_authors>Petkovska I</pubmed_authors><pubmed_authors>Sosa RE</pubmed_authors><pubmed_authors>Gibbs P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Can MRI radiomics distinguish residual adenocarcinoma from acellular mucin in treated rectal cancer?</name><description>&lt;h4>Background&lt;/h4>We explored the use of MRI T2-weighted imaging (T2WI) radiomics to help distinguish acellular mucin from cellular mucin (residual tumor) to inform patient management.&lt;h4>Methods&lt;/h4>This retrospective, multi-institutional study included consecutive patients with rectal adenocarcinoma containing mucin on restaging MRI from March 2012-January 2020. Radiologists segmented 3-mm-thick T2WI. Data were split into training (n = 122), validation (n = 40), and test (n = 42) sets. Sensitivity, specificity, PPV, NPV, and AUC of the developed radiomic models were investigated on the test set. Histopathology was the reference standard. Two radiologists independently reviewed 42 patients using a unique five-point Likert scale for the probability of cellular mucin. DeLong-Delong or McNe</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-07-16T23:39:03.802Z</modification><creation>2026-07-12T03:11:44.219Z</creation></dates><accession>S-EPMC11892329</accession><cross_references><pubmed>39923594</pubmed><doi>10.1016/j.ejrad.2025.111986</doi></cross_references></HashMap>